3 completed, 2 recruiting, 1 terminated, 1 unknown. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Central Nervous System Vascular Malformations: new trials by email Literature Review of Central Nervous System Vascular Malformations trials Research Report on Central Nervous System Vascular Malformations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations Bevacizumab, Placebo - Cerebral AV Malformation | Phase 2 / Phase 3 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 54 | 2026-01-16 | 2026-01-22 |
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 REC-994, Placebo - Cerebral Cavernous Malformation | Phase 2 | Completed | Recursion Pharmaceuticals Inc. | 62 | 2022-03-17 | 2026-10-22 |
| Lovastatin for Treatment of Brain Arteriovenous Malformations Lovastatin, Placebo - Cerebral Arteriovenous Malformation | Phase 2 | Unknown | Beijing Tiantan Hospital | 1244 | 2021-01-01 | 2020-03-09 |
| UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions Cognitive Sparing Brain Stereotactic Radiosurgery (SRS) - Brain Metastases, Adult, Neurocognitive Function | Phase 2 | Recruiting | Jona Hattangadi-Gluth | 90 | 2019-05-01 | 2026-09-08 |
| Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial Atorvastatin, Placebo - Cerebral Cavernous Malformation | Phase 1 / Phase 2 | Completed | University of Chicago | 80 | 2018-07-17 | 2025-08-22 |
| Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation Propranolol - Cerebral Cavernous Malformation | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 71 | 2018-04-11 | 2022-02-25 |
| Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation Propranolol, DNA and RNA Analysis - Cerebral Cavernous Malformations | Phase 2 | Terminated | St. Joseph's Hospital and Medical Center, Phoenix | 4 | 2018-01-24 | 2024-04-19 |
Hemangioma, Cavernous, Central Nervous System (4) · Intracranial Arteriovenous Malformations (3) · Brain Neoplasms (1) · Meningioma (1) · Neoplasms (1)
Brain Diseases (7) · Cardiovascular Abnormalities (7) · Cardiovascular Diseases (7) · Central Nervous System Diseases (7) · Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Nervous System Diseases (7) · Nervous System Malformations (7) · Vascular Diseases (7) · Vascular Malformations (7) · Neoplasms by Histologic Type (5) · Neoplasms, Vascular Tissue (5) · Cavernous Sinus Syndromes (4) · Hemangioma (4)
Propranolol (2) · Atorvastatin (1) · Bevacizumab (1) · DNA (1) · Lovastatin (1)
Beijing Tiantan Hospital (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Jona Hattangadi-Gluth (1) · Mario Negri Institute for Pharmacological Research (1) · Recursion Pharmaceuticals Inc. (1) · St. Joseph's Hospital and Medical Center, Phoenix (1) · University of Chicago (1)
United States (4) · China (1) · France (1) · Italy (1)
Daniel F Hanley, MD (1) · Elisabetta Dejana, Professor (1) · Issam A Awad, MD (1) · Jona Hattangadi-Gluth, MD (1) · Joseph Zabramski, MD (1) · Roberto Latini (1)
PMID 32398113, PMID 36403580, PMID 38419711, PMID 40120614, PMID 40570636, PMID 41117517, PMID 41608890
2017 (1), R01CA238783 (1)